Drug intelligence / Profile preview

LGT-371

Development stage: Unknown
Lead developer: Monash University
Administration: Oral

Overview

**LGT-371** is an investigational orally administered drug candidate developed by Monash University for **moderate-to-severe obstructive sleep apnoea**. It was evaluated in a placebo-controlled, crossover pilot study using a single evening oral capsule dose during in-laboratory polysomnography. The development hypothesis is that LGT-371 reduces ventilatory-control instability, including ventilatory loop gain and chemoreceptor sensitivity, thereby decreasing obstructive sleep apnoea severity. Publicly available trial records do not disclose its chemical structure, molecular target, or a non-code generic name.

Beyond the preview

Go deeper on LGT-371.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LGT-371.

Explore the full profile